Emirodatamab
Based on 1 Customer Validation
Emirodatamab (AMG 427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.05%
- No. CAS: 2449199-61-3
- Peso molecular:105.892 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
Isotype
(scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc
Species Reactivity
Human
IC50 & Target
CD3E & FLT3
In Vitro
Emirodatamab potently induces cytotoxicity in primary AML blasts with high FLT-3 expression under ex vivo conditions, and its activity is enhanced when combined with anti-PD-1 antibodies[2].
Emirodatamab mediates in vitro killing of primary AML cells in a manner dependent on FLT3 expression levels and effector-to-target cell ratio, and its activity is enhanced when combined with anti-PD-1 antibodies[4].
Emirodatamab induces potent, target-specific sub-picomolar TDCC effects in FLT3-expressing human AML cell lines, accompanied by T cell activation and cytokine secretion; it retains complete killing activity against target cells even in the presence of disease-relevant concentrations of sFLT3 or sFLT3L[5].
Emirodatamab exhibits lower potency against PD-L1-expressing MOLM-13 AML cells compared to parental MOLM-13 AML cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Emirodatamab (0.01-1 mg/kg; intravenous injection; once every 7 days; 6 doses total) significantly prolongs the survival of mice bearing orthotopic EOL-1 AML xenografts[5].
Emirodatamab (Cmax=1-10 nM; intravenous injection; 3 administrations) dose-dependently eliminates FLT3-expressing hematopoietic progenitor cells in cynomolgus monkeys, reduces FLT3 transcript levels in bone marrow and blood by up to 97%, and induces T cell activation and cytokine release[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID mcie with Acute myeloid leukemia (female, 7 weeks old, orthotopic xenograft via intravenous injection of 107 MOLM-13_Luc cells, sublethally irradiated)[5]
-
Dosage:0.12 mg/kg; 0.6 mg/kg; 3 mg/kg
-
Administration:i.v.; every 5 days; 6 doses (days 7, 12, 17, 22, 27, 34)
-
Result:Prolonged survival significantly at all doses tested, with median survival times of 36.5 days (3 mg/kg), 37 days (0.6 mg/kg), and 42.5 days (0.12 mg/kg).
All control group mice died within 20 days with a median survival of 18 days.
Remained above the in vitro TDCC EC50 (1.9 pM) in serum for at least 9 days following the final administration.
-
Animal Model:NOD/SCID mice with Acute myeloid leukemia (female, 7 weeks old, orthotopic xenograft via intravenous injection of 5 × 106 EOL-1 cells, sublethally irradiated)[5]
-
Dosage:0.01 mg/kg; 0.1 mg/kg; 1 mg/kg
-
Administration:i.v.; every 7 days; 6 doses (days 9, 16, 23, 30, 37, 44)
-
Result:Prolonged survival significantly at all doses tested; ≥50% of treated animals survived until the study end on day 108 (17/30 total treated animals), while control group mice had a median survival of 36-37 days and were all euthanized by day 52.
-
Animal Model:Cynomolgus monkeys[5]
-
Dosage:Doses intended to achieve maximal serum concentrations (Cₘₐₓ) of 1 nM; 5 nM; 10 nM
-
Administration:i.v.; 3 doses (days 1, 2, and 5)
-
Result:Reduced bone marrow FLT3 transcript levels by 85-95% on day 4 and 93-97% on day 8 across all dose groups.
Reduced blood FLT3 transcript levels to nearly undetectable levels (≥97% reduction) at the earliest tested time point and maintained across all exposures and time points.
Induced T cell activation (upregulation of CD69) and increases in serum IFNγ, IL-6, MCP-1, and TNFα in response to the first dose, with cytokine responses attenuated in subsequent doses.
Increased soluble FLT3L levels dose-dependently, reaching maximum levels of 12,000-23,000 pg/mL per group.
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- Patient-Derived Xenograft (PDX)
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Subcutaneous Cell-Line-Derived Xenograft
- Research Protocol for Cancer Immunology
- Orthotopic Cell-Line Xenograft
- Cell Viability Determination by MTT Colorimetric Assay
- Intraperitoneal/Peritoneal Dissemination Xenograft
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
(scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc
Aplicación
ELISA, FACS, Functional assay, Research in vivo
Verified Bioactivity
-
Immobilized CD3 epsilon Protein, Human (HEK293, His, HY-P70506) can bind Emirodatamab. The EC50 for this effect is 26.57 ng/mL. -
Immobilized FLT3 Protein, Human (T227M, HEK293, His, HY-P75183) can bind Emirodatamab. The EC50 for this effect is 11.97 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Emirodatamab (HY-P99916). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Flow cytometric analysis of 1X106 THP-1 cells labeling FLT3 with Emirodatamab (HY-P99916, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
No. CAS 2449199-61-3
-
Appearance Liquid
-
Peso molecular 105.892 kDa
-
Color Colorless to light yellow
-
SMILES
[Emirodatamab]
-
Synonyms
AMG 427
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (282 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Obszański P, et al. Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia. Molecules. 2022;27(12):3911. Published 2022 Jun 18. [Content Brief]
[2]. Morse JW, et al. Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets. Expert Opin Investig Drugs. 2023;32(2):107-125. [Content Brief]
[3]. Einsele H, et al. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126(14):3192-3201. [Content Brief]
[4]. Daver N, et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35(7):1843-1863. [Content Brief]
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics TCE (T cell engager) Potential in Solid Tumors
T-cell engagers (TCEs) are engineered immunotherapeutic molecules designed to redirect endogenous T cells toward tumor cells through simultaneous binding of a T-cell receptor component, most commonly CD3, and a tumor-associated antigen (TAA) expressed on malignant cells.
2026-06-18
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Emirodatamab
- 2449199-61-3
- AMG 427
- AMG427
- AMG-427
- FLT3
- CD3
- TNF Receptor
- Cluster of differentiation antigen 135
- CD135
- Fms like tyrosine kinase 3
- Cluster of differentiation 3
- Tumor Necrosis Factor Receptor
- TNFR
- T cells
- mouse xenograft models
- cynomolgus monkeys
- acute myeloid leukemia
- AML cells
- MOLM-13 AML cells
- AML cell lines
- relapsed/refractory acute myeloid leukemia
- Inhibitor
- inhibitor
- inhibit